Last Updated : July 28, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tabrecta | capmatinib | Metastatic non-small cell lung cancer (NSCLC) | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Tafinlar | Dabrafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Melanoma Adjuvant Therapy | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar & Mekinist in combo | Dabrafenib & Trametinib in combo | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar and Mekinist | Dabrafenib and Trametinib | NSCLC BRAF V600 | Reimburse with clinical criteria and/or conditions | Complete | ||
Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric high-grade glioma with BRAF V600E | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric low-grade glioma with BRAF V600E | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
Tagrisso | Osimertinib | Non-Small Cell Lung Cancer (NSCLC) (first line) | Reimburse with clinical criteria and/or conditions | Complete |